Travere Therapeutics (TVTX) Non-Current Assets (2016 - 2025)
Historic Non-Current Assets for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $167.5 million.
- Travere Therapeutics' Non-Current Assets fell 678.97% to $167.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $695.3 million, marking a year-over-year decrease of 295.34%. This contributed to the annual value of $177.4 million for FY2024, which is 307.02% up from last year.
- Per Travere Therapeutics' latest filing, its Non-Current Assets stood at $167.5 million for Q3 2025, which was down 678.97% from $175.7 million recorded in Q2 2025.
- Travere Therapeutics' Non-Current Assets' 5-year high stood at $203.3 million during Q1 2023, with a 5-year trough of $146.6 million in Q3 2023.
- Its 5-year average for Non-Current Assets is $184.7 million, with a median of $186.1 million in 2022.
- As far as peak fluctuations go, Travere Therapeutics' Non-Current Assets crashed by 2338.52% in 2023, and later skyrocketed by 2254.13% in 2024.
- Over the past 5 years, Travere Therapeutics' Non-Current Assets (Quarter) stood at $193.8 million in 2021, then dropped by 3.95% to $186.1 million in 2022, then decreased by 7.53% to $172.1 million in 2023, then grew by 3.07% to $177.4 million in 2024, then decreased by 5.61% to $167.5 million in 2025.
- Its Non-Current Assets stands at $167.5 million for Q3 2025, versus $175.7 million for Q2 2025 and $174.6 million for Q1 2025.